Drugs / Glycerin

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) PROCALAMINE 1982-05-06 fda.gov

Trials 14 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06375343 Jan 2026 → Jan 2027 expected dry eye syndrome Laboratorios Sophia S.A de C.V. Not yet recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00243711 Sep 2005 → Apr 2006 dry eye syndrome Allergan Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03197922 Oct 2017 → Nov 2022 autism spectrum disorder, bowel dysfunction Emory University Completed No outcome recorded
Phase 45 trials
Phase 4 NCT05821309 Jun 2023 → Jul 2026 overdue constipation disorder Indiana University Recruiting No outcome recorded
Phase 4 NCT03355326 Oct 2017 → Oct 2020 gastroschisis Indiana University Terminated No outcome recorded
Phase 4 NCT02833415 Mar 2016 → Jan 2018 obesity disorder University of Texas Southwestern Medical Center Completed No outcome recorded
Phase 4 NCT02435069 Feb 2016 → Mar 2017 neurogenic bowel Nemours Children's Clinic Completed No outcome recorded
Phase 4 NCT00987727 Nov 2009 → Jul 2010 dry eye syndrome Allergan Completed No outcome recorded
Phase not applicable6 trials
NCT05660681 Dec 2022 → Aug 2023 dry eye syndrome Calm Water Therapeutics LLC Completed No outcome recorded
NCT02383758 Feb 2015 → Jan 2017 autism spectrum disorder, bowel dysfunction Emory University Completed No outcome recorded
NCT01799629 Mar 2013 → Dec 2022 King Faisal Specialist Hospital & Research Center Terminated No outcome recorded
NCT00681265 Jun → Aug 2008 dry eye syndrome Calm Water Therapeutics LLC Completed No outcome recorded
NCT00514852 Oct 2007 → Jan 2008 dry eye syndrome Allergan Completed No outcome recorded
NCT00544713 Sep 2007 → Jun 2008 dry eye syndrome Allergan Completed No outcome recorded
Also used as a comparator or background therapy in 14 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01335386 Comparator Apr → Jul 2010 constipation disorder Ferring Pharmaceuticals Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01474499 Comparator Sep 2011 → Mar 2012 constipation disorder Ferring Pharmaceuticals Completed No outcome recorded
Phase 47 trials
Phase 4 NCT07676084 Comparator Jun → Oct 2026 expected dry eye syndrome Andover Research Eye Institute Recruiting No outcome recorded
Phase 4 NCT07342413 Comparator Feb → May 2026 overdue vein disorder Goldman, Butterwick, Fitzpatrick and Groff Not yet recruiting No outcome recorded
Phase 4 NCT06491394 Comparator Nov 2024 → Mar 2025 myopathy Aswan University Hospital Completed No outcome recorded
Phase 4 NCT02117687 Comparator May 2014 → Jan 2015 dry eye syndrome Allergan Completed No outcome recorded
Phase 4 NCT02120079 Comparator Feb 2014 → Apr 2017 dry eye syndrome Tufts Medical Center Completed No outcome recorded
Phase not applicable5 trials
NCT05723731 Background Jan → Jul 2023 constipation disorder Air Force Military Medical University, China Terminated No outcome recorded
NCT02153606 Comparator Jan 2015 → Jun 2016 McMaster University Unknown No outcome recorded
NCT02149407 Comparator May 2014 → May 2016 King Saud Medical City Unknown No outcome recorded
NCT01746511 Comparator Jul 2012 → Sep 2013 hyperbilirubinemia University of Rochester Completed No outcome recorded
NCT00932477 Comparator Aug → Sep 2009 dry eye syndrome Allergan Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 28 sources stand behind the page.

FieldValueCited text
Known as glycerin “Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its...” NCT02120079
23

“Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.” NCT05723731

“Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.” NCT06375343

“Carboxymethylcellulose and GlycerinNCT00756678

NCT00987727

NCT05821309

NCT07676084

NCT06491394

NCT03197922

NCT02153606

NCT01799629

NCT02383758

NCT00544713

NCT00243711

NCT00514852

NCT07342413

NCT02435069

NCT00938704

NCT02117687

NCT03355326

NCT02149407

NCT00681265

NCT05660681

NCT01746511

Known as [U-13C3] glycerol ClinicalTrials.gov intervention name — accepted as the source's own label NCT02833415
Known as Glycerin and Polysorbate 80 based artificial tear ClinicalTrials.gov intervention name — accepted as the source's own label NCT00932477
Known as Glycerine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474499
1

NCT01335386

Known as USP Glycerin USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily.” NCT02435069
Modality Other / unclassified “Carboxymethylcellulose and Glycerin based artificial tear” NCT00544713
Route Other “1 to 2 drops into each eye as needed but at least twice daily” NCT00514852